Antioxidant effects of gold nanoparticles on Schistosoma mansoni induced granuloma, in vitro

Document Type : Research Paper


1 Zoology and Entomology Department, Faculty of Science, Helwan University, Egypt

2 Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Egypt


Objective(s): Schistosomiasis and hepatitis C virus [HCV] co-infection is common among the Egyptian population. Co-infected patients have higher rate of chronic hepatitis, cirrhosis and hepatocellular carcinoma. The aim of the present study was to investigate the potential role of gold nanoparticles on granuloma in vitro.
Materials and Methods: In the current study, granulocytes were isolated from the blood of 50 Schistosoma/HCV co-infected patients and 25 healthy subjects. Granulocytes were used to induce granuloma in vitro in the presence of polyacrylamide beads coated with Schistosoma mansoni soluble egg antigen and interleukin-17. In addition, granuloma was treated on the 3rd day with gold nanoparticles alone or in the presence of human hepatocellular carcinoma cell line (Hep G2) as carcinoma model. Praziquantel (PZQ) was used as a positive control. Granuloma index was determined on the 7th and 14th day. Furthermore, the supernatants were collected to measure the granulocyte mediators including tumor necrosis factor alpha [TNF-α], hydrogen peroxide [H2O2] and nitric oxide [NO] by ELISA on the 7th and 14th day.
Results: Treatment with AuNPs in the presence of Hep G2 showed a significant reduction in granuloma index and granulocyte mediators including H2O2 and NO, while a significant elevation was observed in TNF-α level as compared to their corresponding values in the presence of IL-17 in both healthy individual and co-infected patients on the 7th and 14th day.
Conclusion: In conclusion, the presence of IL-17 accelerated the formation of granuloma and the treatment with AuNPs in the presence Hep G2 cells indicated that AuNPs were more effective antioxidant agents than PZQ.


1.Kamal SM, Rasenack JW, Bianchi L. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4[+] T-cell and cytokine response. Gastroenterology. 2001; 121: 646-656.
2.Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006; 43: 915-922.
3.Kamal S, Madwar M, Bianchi L. Clinical, virological, and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281-289.
4.Hammad HA, el Fattah MM, Moris M, Madina EH, el Abbasy AA, Soliman AT. Study on some hepatic functions and prevalence of hepatitis B surface antigenaemia in Egyptian children with schistosomal hepatic fibrosis. J Trop Pediatr.1990; 36: 126-127.
5.Mabrouk GM. Prevalence of hepatitis C infection and schistosomiasis in Egyptian patients with hepatocellular carcinoma. Dis Markers. 1997; 13: 177-182.
6.Badawi AF and Michael MS. Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis-B viral infection and schistosomiasis. Anticancer Res. 1999; 19: 4565-4569.
7.Iacovacci S, Sargiacomo M, Parolini I, Ponzetto A, Peschle C, Carloni G. Replication and multiplication of hepatitis C virus genome in human foetal liver cells. Res Virol. 1993; 144: 275-279.
8.Ito T, Mukaigawa J, Zuo J, Hirabayashi Y, Mitamura K, Yasui K. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. J Gen Virol. 1996; 77(5): 1043-1054.
9.Seipp S, Mueller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T. Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol. 1997; 78(10): 2467-2476.
10.Song ZQ, Hao F, Ma QY, Wang YM. [In vitro infection of human liver cancer cell line HepG2 with HCV]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2003; 17: 77-80.
11.Butterworth AE, Sturrock RF, Ouma JH. Comparison of different chemotherapy strategies against Schistosoma mansoni in Machakos District, Kenya: effects on human infection and morbidity. Parasitology. 1991; 103(3): 339-355.
12.Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995; 53: 61-62.
13.Ismail M, Botros S, Metwally A. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999; 60: 932-935.
14.King CH, Muchiri EM, Ouma JH. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis. 2000; 6: 585-594.
15.Kenworthy JD, Ye P, Wu GC. Field evaluation of a test for praziquantel resistance in Schistosoma sp. Vet Parasitol. 2003; 113: 83-87.
16.Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008; 21: 659-667.
17.Utzinger J, Raso G, Brooker S. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology. 2009; 136: 1859-1874.
18.Ali SA, El-Regal NS, Saeed SM. Antischistosomal Activity of Two Active Constituents Isolated from the Leaves of Egyptian Medicinal Plants. Infect Dis [Auckl]. 2015; 8: 5-16.
19.O’Hagan DT, Rahman D, McGee JP. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 1991; 73: 239-242.
20.Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine. 2004; 22: 1423-1432.
21.Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol. 2011; 127: 627-636.
22.Vieites M, Smircich P, Guggeri L. Synthesis and characterization of a pyridine-2-thiol N-oxide gold[I] complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J Inorg Biochem. 2009; 103: 1300-1306.
23.Dkhil MA, Bauomy AA, Diab MS, Al-Quraishy S. Antioxidant and hepatoprotective role of gold nanoparticles against murine hepatic schistosomiasis. Int J Nanomedicine; 10: 7467-7475.
24.Li JJ, Hartono D, Ong CN, Bay BH, Yung LY. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials; 31: 5996-6003.
25.Yepes E, Varela MR, Lopez-Aban J, Dakir el H, Mollinedo F, Muro A. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine. PLoS One. 9: e109431.
26.Paino IM, Marangoni VS, de Oliveira Rde C, Antunes LM, Zucolotto V. Cyto and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral blood mononuclear cells. Toxicol Lett. 215: 119-125.
27.Nady S, Shata MT, Mohey MA, El-Shorbagy A. Protective Role of IL-22 against Schistosoma mansoni Soluble Egg Antigen- Induced Granuloma in vitro. Parasit immunol. 2017; 39(1).
28.Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Analytical biochemistry. 1982; 126: 131-138.
29.Chen PC, Mwakwari SC, Oyelere AK. Gold nanoparticles: From nanomedicine to nanosensing. Nanotechnol Sci Appl. 2008; 1: 45-65.
30.Peng Y, Wu J, Wang J, Li W, Yu S. Study and evaluation of Wondfo rapid diagnostic kit based on nano-gold immunochromatography assay for diagnosis of Plasmodium falciparum. Parasitol Res. 110: 1421-1425.
31.Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small. 2007; 3: 1840-1854.
32.Li L, Fan M, Brown R, Van LJ, Wang J, Wang W, Song Y, Zhang P. Synthesis, Properties and environmental applications of nanoscale iron-based materials; a review. EnViron Sci Technol. 2006; 36: 405-431.
33.Tomuleasa C, Soritau O, Orza A. Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. J Gastrointestin Liver Dis; 21: 187-196.
34.Dkhil MA, Bauomy AA, Diab MS, Wahab R, Delic D, Quraishy S. Impact of gold nanoparticles on brain of mice infected with Schistosoma mansoni. Parasitol Res. 114: 3711-3719.
35.Yen HJ, Hsu SH, Tsai CL. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small. 2009; 5: 1553-1561.
36.Tournebize J, Boudier A, Joubert O. Impact of gold nanoparticle coating on redox homeostasis. Int J Pharm. 438: 107-116.
37.Risom L, Moller P, Loft S. Oxidative stress-induced DNA damage by particulate air pollution. Mutat Res. 2005; 592: 119-137.
38.Kajita M, Hikosaka K, Iitsuka M, Kanayama A, Toshima N and Miyamoto Y. Platinum nanoparticle is a useful scavenger of superoxide anion and hydrogen peroxide. Free Radic Res 2007; 41: 615-626.
39.Bahgat MM, El-Far MA, Mesalam AA, Ismaeil AA, Ibrahim AA, Gewaid HE, Maghraby AS, Ali MA, Abd-Elshafy D N. Schistosoma mansoni soluble egg antigens enhance HCV replication in mammalian cells. J Infect Dev Ctries. 2010; 4: 226-234.